GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » Capex-to-Operating-Income

Concord Drugs (BOM:538965) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Concord Drugs's Capital Expenditure for the three months ended in Dec. 2023 was ₹0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was ₹2.40 Mil.

Hence, Concord Drugs's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.00.


Concord Drugs Capex-to-Operating-Income Historical Data

The historical data trend for Concord Drugs's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs Capex-to-Operating-Income Chart

Concord Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.45 1.84 0.27 0.28

Concord Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Concord Drugs's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Capex-to-Operating-Income falls into.



Concord Drugs Capex-to-Operating-Income Calculation

Concord Drugs's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-8.566) / 30.555
=0.28

Concord Drugs's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 2.398
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Drugs  (BOM:538965) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Concord Drugs Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Concord Drugs's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs (BOM:538965) Business Description

Traded in Other Exchanges
N/A
Address
3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines